Abstract
The objective of this review is to evaluate the cost-effectiveness of antimicrobial therapy treatment for inpatients infected with Klebsiella pneumoniae carbapenemase.More specifically, the review question is: What is the best evidence on the cost-effectiveness of the antimicrobial treatment for inpatients infected with Klebsiella Pneumoniae Carbapenemase?"
MeSH terms
-
Anti-Infective Agents / economics*
-
Bacterial Proteins
-
Cost-Benefit Analysis
-
Cross Infection / drug therapy*
-
Cross Infection / economics
-
Humans
-
Inpatients / statistics & numerical data*
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / economics
-
Klebsiella pneumoniae*
-
Research Design
-
Systematic Reviews as Topic
-
beta-Lactamases
Substances
-
Anti-Infective Agents
-
Bacterial Proteins
-
beta-Lactamases
-
carbapenemase